Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California

 

Recent News and Articles on the Keywords: pharma + 0.33 + 583  Related to the article below (Last Update: 8/5/2008)

India's Aurobindo Pharma gets US FDA final approval for generic ...
Forbes, NY -
At 12.21 pm Aurobindo Pharma was up 1.39 percent at 306.80 rupees on the Bombay Stock Exchange and the benchmark Sensex was down 0.33 percent at 14529.21 ...PINK:AUBPF - BOM:524804 - MRK
Mutual Fund NAVs end higher
Moneycontrol.com, India -
Selling pressure was seen in major oil, capital goods, select banking and power while buying in metal, pharma and select technology stocks. ...
US STOCKS-Biotech lifts Nasdaq; S&P 500, Dow cut losses
Reuters - Jul 31, 2008
SPX shed 4.28 points, or 0.33 percent, to 1279.98. The Nasdaq Composite Index .IXIC gained 7.75 points, or 0.33 percent, to 2337.47. ...
Richard Aster Jr Buys Cooper Industries Ltd., Covidien Ltd ...
GuruFocus.com, TX -
The impact to his portfolio due to this purchase was 0.33%. His holdings were 773005 shares as of 06/30/2008. Blackbaud is the leading global provider of ...CEPH - AEO - SCUR
Sgx Pharmaceuticals Inc (SGXP) holdings reduced by Dimensional ...
Mffais.com, CA - Aug 2, 2008
The stock is currently owned by 16 funds/institutions with a total activity score of 0.33. With 40.00 % of owning funds reported recently buying shares, ...

Sify
Mkts surged in late trade; banks, pharma
Moneycontrol.com, India - Jul 21, 2008
European markets have bounced back in mid session and trading in green, at the time of writing market report. FTSE was up 0.33%, CAC 0.96% and DAX 0.55%.
Indian market trading weak amid profit booking RTT News
all 121 news articles »
Mkts surged in late trade; banks, pharma, auto stks gain
Moneycontrol.com, India - Jul 21, 2008
FTSE was up 0.33%, CAC 0.96% and DAX 0.55%. Markets are trading strong on the back of buying in banking, pharma, realty, FMCG, metal, auto, select oil and ...
DSM reports best quarter ever and raises full-year outlook
MarketWatch - Jul 29, 2008
The Pharma and Performance Materials cluster showed steady organic growth. Within Base Chemicals & Materials all businesses showed a negative volume growth, ...
DSM reports best quarter ever and raises full-year outlook Ad-Hoc-News (Pressemitteilung)
all 15 news articles »
Teva Reportedly To Acquire Barr Pharma
RTT News, NY - Jul 16, 2008
TEVA closed the day's trade up 0.33% at $42.41 on a volume of 8.23 million shares. In after-hours, the stock shed 2.10% and was at $41.52. by RTT Staff ...TEVA - BRL
OSI Pharmaceuticals Announces Second Quarter 2008 Financial Results
MarketWatch - Jul 23, 2008
OSI Pharmaceuticals is committed to "shaping medicine and changing lives" by discovering, developing and commercializing high-quality and novel ...OSIP - DNA
Source: Google News

[PDF] Simulataneous Determination of Nimesulide and its Impurities in Pharmaceutical Formulations by …
B Tubic, B Ivkovic, M Zecevic, S Vladimirov - ACTA CHIMICA SLOVENICA, 2007 - acta.chem-soc.si
Page 1. 583 Acta Chim. Slov. 2007, 54, 583?590 ... Scientific paper Simulataneous
Determination of Nimesulide and its Impurities in Pharmaceutical Formulations ...

The essential oils of Eucalyptus camaldulensis and its natural hybrid (clone 583) from Morocco -
A Farah, M Fechtal, A Chaouch, S Zrira - FLAVOUR AND FRAGRANCE JOURNAL, 2002 - doi.wiley.com
... Those most used in cosmetic and pharmaceutical industry contain more ... 1253 Piperitone
0.33 0.35 ... ESSENTIAL OILS OF EUCALYPTUS CAMALDULENSIS AND CLONE 583 397 ...

Scaleup of a Pharmaceutical Granulation in Planetary Mixers -
M Land?n, P York, MJ Cliff, RC Rowe - Pharmaceutical Development and Technology, 1999 - informaworld.com
... 0.109 3.602 9.7 80 523 0.061 0.33 0.109 3.602 17.8 150 583 0.134 0.34 0.109 3.602
21.3 240 801 0.413 0.45 ... Page 5. Pharmaceutical Granulation in Planetary Mixers ...

Chemometric Quantitation of the Active Substance (Containing CN) in a Pharmaceutical Tablet Using … -
M Dyrby, SB Engelsen, L N?rgaard, M Bruhn, L … - 2002 - ingentaconnect.com
... Tablet Samplir??, a sampling device specially made for measuring pharma- ceutical
tablets ... Page 5. APPLIED SPECTROSCOPY 583 ... with iPLS 8432?9273 3 0.33 0.96 ...

Human pharmaceuticals in US surface waters: A human health risk assessment -
BW Schwab, EP Hayes, JM Fiori, FJ Mastrocco, NM … - Regulatory Toxicology and Pharmacology, 2005 - Elsevier
... Elsevier Inc. All rights reserved. Human pharmaceuticals in US surface
waters: A human health risk assessment. Bradley W. Schwab ...

Warner-Lambert/Parke-Davis Pharmaceutical Research
SJ Hays, CC Huang - Journal of Labelled Compounds and Radiopharmaceuticals - doi.wiley.com
... Sheryl J. Hays and CC Huang Warner-Lambert/Parke-Davis Pharmaceutical Research ... HCOOH
(9:1:.1) Rf = 0.33. Plates were radiochemically analyzed using a ...

TLC supplemented by UV spectrophotometry compared with HPLC for separation and determination of some … -
R Bhushan, D Gupta, A Jain - JPC-Journal of Planar Chromatography-Modern TLC, 2006 - akademiai.com
... 80 (Panacea Biotec, New Delhi, India), and glibenclamide, mar- keted as Daonil-5
(Aventis Pharma, Mumbai, India), were obtained for these studies. ...

[PDF] New Diazo Coupling Reactions for Visible Spectrophotometric Determination of Alfuzosin in …
MV KRISHNA, DG SANKAR - e-journals.in
... Analysis of pharmaceutical preparations Application of the proposed methods to the ...
99.9?0.43 99.9?0.55 100.2?0.85 100.1?0.33 100.01?0.53 ... 2006, 7, 583. ...

Patent citation analysis of Allergan pharmaceutical patents -
ME Mogee, RG Kolar - etp, 1998 - Expert Opinion
... In the analysis, all 583 Allergan patents were subjected to co-citation clustering. ...
1326 Patent citation analysis of Allergan pharmaceutical patents 24-2 ... 0.33 ...

Antiosteoporotic Activity of the Water Extract of Dioscorea spongiosa -
J Yin, Y Tezuka, K Kouda, QL Tran, T Miyahara, Y … - Biological & Pharmaceutical Bulletin, 2004 - J-STAGE
... 583 ... c Shenyang Pharmaceutical University; 105 Wenhua Road, Shenyang, China. ... X-axis
(anti-fracture) 4.87 0.86 3.51 0.51 ## 4.15 0.94* 3.91 0.36 3.64 0.33 ...

Source: Google Scholar

Peregrine Pharmaceuticals Submits Clinical Protocol To Initiate Bavituximab Phase II Trial In Lung Cancer Patients
Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and hepatitis C virus (HCV) infection, today announced that it has submitted a clinical protocol with the Drug Controller General of India (DCGI) for a Phase II trial of bavituximab in combination with chemotherapy in patients with non-small cell lung cancer (NSCLC). The multi-center trial is expected to begin enrolling patients once the protocol regulatory review is completed.
The trial has a two-stage design. Up to 21 NSCLC patients will be enrolled initially and the study will be expanded up to a total of 49 patients if positive results are observed in the first cohort. The primary objective of the Phase II study is to assess overall response rate to the combination of bavituximab and chemotherapy. Secondary objectives include measuring time to tumor progression, duration of response, overall patient survival and safety parameters. Patients will receive up to six cycles of chemotherapy with weekly administration of bavituximab until their cancer progresses.

"Submitting this Phase II clinical protocol represents a significant milestone for the bavituximab cancer program," said Steven W. King, president and CEO of Peregrine. "This trial builds on data generated from a recently completed Phase Ib clinical study in which bavituximab was administered in combination with chemotherapy, including carboplatin and paclitaxel. Results from that study indicated that the combination of bavituximab with paclitaxel and carboplatin was particularly promising, with encouraging signs of anti-tumor activity and a safety profile that appeared to be consistent with chemotherapy alone. We look forward to assessing its potential in this larger trial in patients with non-small cell lung cancer, a condition that currently lacks effective treatment options."

Tumor response will be evaluated every other month using Response Evaluation Criteria in Solid Tumors (RECIST) criteria. The trial is being conducted according to International Conference on Harmonization (ICH) and Good Clinical Practices (GCP) guidelines.

Bavituximab is a monoclonal antibody that binds to a phospholipid called phosphatidylserine (PS), normally located inside normal cells, but which becomes exposed on the outside of the cells that line the blood vessels of tumors, creating a specific target for anti-cancer treatments. Bavituximab is believed to help mobilize the body's immune system to destroy the blood vessels needed for tumor growth and spread. In a Phase Ib trial to assess its safety in combination with common chemotherapy agents in advanced cancer patients with metastatic disease, bavituximab plus chemotherapy appeared to have a safety profile consistent with chemotherapy alone and showed positive signs of clinical activity, achieving objective response or disease stabilization in 50% of the evaluable patients. Bavituximab is currently in clinical trials in the U.S. in patients with advanced solid tumors and in patients co-infected with HCV and HIV.
About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus (HCV) infection. The company is pursuing five separate clinical trials in cancer and HCV infection in the U.S. and India with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (http://www.avidbio.com), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at http://www.peregrineinc.com

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that results from this Phase II trial will not correlate with the results from the Phase Ib trial, the risk that bavituximab will not be as well tolerated by patients with non small cell lung cancer, and the risk that enrollment rates in the trial will be slower than anticipated. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by all a number of other factors, including the risk factors listed from time to time in the Company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2007. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

Peregrine Pharmaceuticals, Inc.
http://www.peregrineinc.com
 
 
Google
Web www.iconocast.com

Search inside Iconocast for the keyword you have in mind.

Iconocast has collected more than 50,000 articles and press releases on health and science.

These are current and most up to date press releases on the subject you are searching.

We collect current health and science press releases daily from more than 5000 research and health institutes. Here is an example : The elderberry way to perfect skin

We believe if you do search inside Iconocast, you will get better results than searching the web alone.

 
 
Continue News With: News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services.

 

Iconocast Home Page

Contact Iconocast

© 2003-07. ICONOCAST is a trademark of iconocast.com.